CLINICAL TRIALS PROFILE FOR SANDOSTATIN

505(b)(2) Clinical Trials for Sandostatin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT01175096 ↗	Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor	Unknown status	Novartis	Phase 1/Phase 2	2010-07-01	RAD001 continues to be investigated as an anticancer agent on new indications such as neuroendocrine tumors (incl. carcinoid), breast cancer, liver cancer, gastric cancer and lymphoma based on its potential to act: - directly on the tumor cells by inhibiting tumor cell growth and proliferation - indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity and VEGF production and VEGF-induced proliferation of endothelial cells) A role for RAD001 in combination with Sandostatin LAR® Depot in the treatment of advanced carcinoid tumor is suggested by data on the regulatory role of mTOR in cell growth and protein translation and the finding that somatostatin-induced growth arrest is mediated in part by inhibition of the PI3K pathway (Charland, et al. 2001). The present study is designed to collect safety/tolerability data and evidences for efficacy of RAD001 in the medically highly unmet indication of advanced pulmonary neuroendocrine tumor in Chinese patients.
New Indication	NCT01175096 ↗	Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor	Unknown status	Guangdong General Hospital	Phase 1/Phase 2	2010-07-01	RAD001 continues to be investigated as an anticancer agent on new indications such as neuroendocrine tumors (incl. carcinoid), breast cancer, liver cancer, gastric cancer and lymphoma based on its potential to act: - directly on the tumor cells by inhibiting tumor cell growth and proliferation - indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity and VEGF production and VEGF-induced proliferation of endothelial cells) A role for RAD001 in combination with Sandostatin LAR® Depot in the treatment of advanced carcinoid tumor is suggested by data on the regulatory role of mTOR in cell growth and protein translation and the finding that somatostatin-induced growth arrest is mediated in part by inhibition of the PI3K pathway (Charland, et al. 2001). The present study is designed to collect safety/tolerability data and evidences for efficacy of RAD001 in the medically highly unmet indication of advanced pulmonary neuroendocrine tumor in Chinese patients.
New Indication	NCT01175096 ↗	Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor	Unknown status	Guangdong Provincial People's Hospital	Phase 1/Phase 2	2010-07-01	RAD001 continues to be investigated as an anticancer agent on new indications such as neuroendocrine tumors (incl. carcinoid), breast cancer, liver cancer, gastric cancer and lymphoma based on its potential to act: - directly on the tumor cells by inhibiting tumor cell growth and proliferation - indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity and VEGF production and VEGF-induced proliferation of endothelial cells) A role for RAD001 in combination with Sandostatin LAR® Depot in the treatment of advanced carcinoid tumor is suggested by data on the regulatory role of mTOR in cell growth and protein translation and the finding that somatostatin-induced growth arrest is mediated in part by inhibition of the PI3K pathway (Charland, et al. 2001). The present study is designed to collect safety/tolerability data and evidences for efficacy of RAD001 in the medically highly unmet indication of advanced pulmonary neuroendocrine tumor in Chinese patients.

All Clinical Trials for Sandostatin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001860 ↗	Sandostatin LAR Depot vs. Surgery for Treating Acromegaly	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	1999-08-01	The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas. The primary goal is to normalize insulin-like growth factor-1 (IGF-1) levels. Secondary goals are to compare Sandostatin LAR® (Registered Trademark) Depot treatment and transsphenoidal surgery to achieve the following goals: suppress growth hormone levels to less than or equal to 2.5 ng/mL, relieve the clinical signs and symptoms of acromegaly, reduce the size of the macroadenomas, produce few side effects, assess the prognostic value of baseline pituitary adenoma size, extension and baseline growth hormone level on post-treatment growth hormone and IGF-1 levels, and assess the resource utilization of each treatment type.
NCT00002252 ↗	A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea	Completed	Sandoz	N/A	1969-12-31	To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.
NCT00002253 ↗	A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Co	Completed	Sandoz	N/A	1969-12-31	The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA 102A). The secondary objectives include: 1) To evaluate clinical efficacy and safety of open-label Sandostatin in patients who were "Non-Responders" in Study #D203 - FDA 102A; 2) To evaluate the efficacy and safety of Sandostatin during prolonged open-label treatment in "Responders" from Study #D03 - FDA 102A.

Clinical Trial Conditions for Sandostatin

Condition Name

Condition Name for Sandostatin
Intervention	Trials
Acromegaly	18
Neuroendocrine Tumors	6
Diarrhea	4

Condition MeSH

Condition MeSH for Sandostatin
Intervention	Trials
Acromegaly	18
Neuroendocrine Tumors	17
Carcinoid Tumor	15

Clinical Trial Locations for Sandostatin

Trials by Country

Trials by Country for Sandostatin
Location	Trials
United States	284
Netherlands	15
Canada	14
Spain	12
Italy	8

Trials by US State

Trials by US State for Sandostatin
Location	Trials
California	14
New York	13
Michigan	12
Florida	12
Massachusetts	11

Clinical Trial Progress for Sandostatin

Clinical Trial Phase

Clinical Trial Phase for Sandostatin
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	13
Phase 3	9

Clinical Trial Status

Clinical Trial Status for Sandostatin
Clinical Trial Phase	Trials
Completed	48
Terminated	9
Unknown status	7

Clinical Trial Sponsors for Sandostatin

Sponsor Name

Sponsor Name for Sandostatin
Sponsor	Trials
Novartis	13
National Cancer Institute (NCI)	10
Novartis Pharmaceuticals	6

Sponsor Type

Sponsor Type for Sandostatin
Sponsor	Trials
Other	85
Industry	37
NIH	15

Clinical Trials Update, Market Analysis, and Projection for Sandostatin (Octreotide)

Last updated: January 27, 2026

Summary

Sandostatin (octreotide) is a synthetic somatostatin analog primarily used in the treatment of acromegaly, neuroendocrine tumors, and certain carcinoid syndromes. This report synthesizes recent clinical trial data, evaluates the current market landscape, and projects future growth trajectories. Emphasizing innovation, regulatory updates, and competitive dynamics, the analysis provides actionable insights for stakeholders.

---

What are the latest clinical developments involving Sandostatin?

Recent Clinical Trials (2021-2023) Overview

Trial ID	Focus Area	Phase	Objectives	Key Outcomes	Date of Completion	Source
NCT04529766	Treatment of Gastroenteropancreatic NETs	Phase III	Evaluate efficacy in combination therapy	Significant tumor control, improved PFS	2023-09-01	ClinicalTrials.gov
NCT04872842	Acromegaly refractory to standard therapy	Phase IV	Assess safety and efficacy	Better biochemical control with tolerable safety profile	2022-12-15	ClinicalTrials.gov
NCT04957836	Managing Carcinoid Syndrome	Phase II	Symptom management effectiveness	Noted reduction in flushing and diarrhea	2023-05-20	ClinicalTrials.gov

Key Clinical Trends

• Combination Therapy Efficacy: Trials exploring octreotide with mTOR inhibitors or targeted therapies indicate enhanced disease control.
• Extended-Release Formulation: Multiple studies assess long-acting formulations to improve patient adherence.
• Biomarker Identification: Growing focus on somatostatin receptor subtype 2 expression as a predictor for treatment response.

Pharmacovigilance and Safety Data (2021-2023)

• Predominant adverse events: gastrointestinal disturbances, gallstones, injection site reactions.
• Serious adverse events are rare (<2%), consistent with prior safety profiles.
• No new safety signals identified in large-scale post-marketing surveillance.

---

Market Analysis of Sandostatin (Octreotide)

Current Market Size and Revenue

Year	Global Market Value (USD billions)	CAGR (2018-2022)	Key Drivers	Regional Breakdown
2022	$1.02	6.5%	Increase in neuroendocrine tumors, expanded indications	North America (40%), Europe (25%), Asia-Pacific (20%), Others (15%)

Market Share and Competitive Landscape

Company	Product	Market Share	Major Differentiator	Pricing (USD per dose)
Novartis	Sandostatin LAR (Long-Acting Release)	70%	Extended-release formulation	~$3,000 per injection
Ipsen	Somatuline Depot (Lanreotide)	20%	Subcutaneous delivery	~$2,800 per dose
Others	Various generics	10%	Cost-efficiency	~$2,000–$2,500

Note: Novartis retains a dominant position as the pioneer and primary supplier worldwide.

Regulatory and Reimbursement Environment

• FDA: Approved for acromegaly, carcinoid syndrome, VIPoma, and tumors expressing somatostatin receptors.
• EMA: Similar indications with additional country-specific approvals.
• Reimbursement: Generally favorable in developed regions, with coverage expanding in emerging markets, contingent on local health policies.

Emerging Market Dynamics

• Developing regions are witnessing increasing adoption driven by enhanced diagnostic capabilities and rising neuroendocrine tumor incidences.
• Pricing pressures and the entrance of biosimilars herald cost mitigation, influencing market share and future revenues.

---

Market Projection (2023-2028)

Year	Projected Market Value (USD billions)	CAGR	Assumptions
2023	$1.10	7.3%	Continued approval expansions, technological advances
2024	$1.18		Slight market penetration of biosimilars
2025	$1.27		Regulatory approvals for new indications; increased off-label use
2026	$1.36		Increased global uptake, especially in Asia-Pacific
2027	$1.45		Growth fueled by combination therapies
2028	$1.55		Emergence of next-generation somatostatin analogs

Key Drivers Influencing Growth

• Expanding Indications: New tumor types and refractory cases.
• Technological Innovation: Longer-acting formulations reducing dosing frequency.
• Regulatory Support: Approvals for combination treatments and new delivery systems.
• Market Penetration: Increased presence in emerging markets.
• Biosimilar Competition: Potential to reduce prices and increase accessibility.

---

Comparison with Key Competitors

Aspect	Sandostatin (Octreotide)	Lanreotide	Pasireotide	Pasireotide-LAR
Approved Indications	Acromegaly, NETs, VIPoma	NETs, Acromegaly	Cushing's disease, Acromegaly	Same as Pasireotide
Delivery	IM injection (long-acting), SC	SC injection	SC injection	SC injection
Pricing (USD per dose)	~$3,000	~$2,800	~$4,200	~$4,200
Market Share (est.)	70%	20%	5%	5%

Sandostatin maintains a dominant position, but biosimilar options may challenge its market share.

---

Regulatory and Policy Outlook

Ongoing Regulatory Developments

• FDA’s Biosimilar Pathway: Potential biosimilar approvals may influence pricing and market dynamics.
• European Medicines Agency (EMA): Encourages biosimilar adoption, reducing costs.
• Local Regulatory Variations: Significant in emerging markets; evolving reimbursement policies can impact access.

Intellectual Property Landscape

• Patent Expiry: Key patents on Sandostatin’s formulations have begun to lapse (notably, U.S. patents expired in 2018), opening avenues for biosimilars.
• Patent Litigation: Ongoing disputes may affect market entry timelines.

---

Deepening Market Insights

Key Opportunities

• Biosimilar Development: Affirms cost-competitiveness.
• Indication Expansion: Focus on refractory or rare tumors.
• Delivery Innovations: Oral formulations or implantable devices.

Potential Challenges

• Competitive substitutes: Newer analogs or peptide receptor radionuclide therapy (PRRT).
• Regulatory delays: Often hinder timely market access.
• Cost pressures: Particularly in lower-income regions.

---

Key Takeaways

• Clinical Innovation: Recent trials bolster the efficacy profile of octreotide in combination therapies. The focus remains on extending progression-free survival and improving patient quality of life.
• Market Power: Novartis' Sandostatin dominates, but biosimilar entrants and alternative therapies pose challenges.
• Growth Trajectory: The market is projected to grow at approximately 7-8% CAGR through 2028, driven by indication expansion and emerging markets.
• Regulatory Landscape: Positive trends favor biosimilar proliferation; ongoing policy adjustments will influence market dynamics.
• Strategic Focus: Stakeholders should monitor clinical trial outcomes, regulatory pathways, and biosimilar developments to optimize positioning.

---

FAQs

Q1. What are the primary indications for Sandostatin?
A1. It is approved for acromegaly, neuroendocrine tumors (including carcinoid tumors), VIPomas, and hormone-secreting tumors expressing somatostatin receptors.

Q2. How do recent clinical trials impact the future use of Sandostatin?
A2. Trials demonstrating enhanced efficacy in combination therapies and long-acting formulations may expand indications and improve patient adherence.

Q3. What is the competitive outlook for Sandostatin with biosimilars entering the market?
A3. Biosimilars are expected to reduce prices and increase accessibility, potentially capturing significant market share from Novartis' original formulation over the next 5 years.

Q4. Which markets offer the highest growth potential for Sandostatin?
A4. Emerging markets in Asia-Pacific and Latin America are poised for high growth due to increasing disease incidence and improving healthcare infrastructure.

Q5. What regulatory trends could influence Sandostatin's market future?
A5. Accelerated approvals for biosimilars, expanded indications, and evolving reimbursement policies are likely to shape market access and competitiveness.

---

References

1. ClinicalTrials.gov. (2023). Recent Sandostatin-related clinical trials.
2. Novartis. (2022). Sandostatin (octreotide) product information.
3. MarketsandMarkets. (2022). Neuroendocrine Tumor Therapeutics Market.
4. U.S. Food & Drug Administration. (2022). Biosimilar pathway updates.
5. European Medicines Agency. (2022). Annual report on somatostatin analogs.

---